Earnings summaries and quarterly performance for Cocrystal Pharma.
Executive leadership at Cocrystal Pharma.
Board of directors at Cocrystal Pharma.
Research analysts covering Cocrystal Pharma.
Recent press releases and 8-K filings for COCP.
Cocrystal Pharma Reports Q3 2025 Financial Results and Pipeline Updates
COCP
Earnings
New Projects/Investments
- Cocrystal Pharma reported a net loss of $2.0 million, or $0.19 per share, for the third quarter of 2025, compared to a net loss of $4.9 million, or $0.49 per share, for the third quarter of 2024.
- The company received FDA IND clearance to evaluate CDI-988 as both a norovirus preventive and treatment, with plans to initiate a Phase 1b norovirus challenge study in Q1 2026.
- As of September 30, 2025, Cocrystal Pharma reported unrestricted cash of $7.7 million and 13.0 million common shares outstanding.
- In September 2025, the company raised $4.7 million in gross proceeds from a registered direct offering, and in October 2025, received a $500,000 NIH SBIR award and completed a private placement for $1.03 million in gross proceeds.
Nov 14, 2025, 1:30 PM
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement
COCP
New Projects/Investments
- Cocrystal Pharma, Inc. completed a private placement on October 28, 2025, raising $1.03 million in gross proceeds.
- Four company insiders purchased 739,426 units at $1.39 per unit.
- Each unit consisted of one share of common stock and one warrant to purchase two shares of common stock at an exercise price of $1.24 per share over a 27-month period.
- The warrants have the potential to generate an additional $1.83 million for the company if fully exercised.
- The net proceeds from this offering are intended to support the company's clinical development programs, working capital, and general corporate purposes.
Oct 30, 2025, 12:00 PM
Cocrystal Pharma Closes Registered Direct Offering and Private Placement
COCP
- Cocrystal Pharma, Inc. announced the closing of a registered direct offering and concurrent private placement on September 15, 2025.
- The company sold 2,764,710 shares of common stock at a purchase price of $1.70 per share.
- This offering generated approximately $4.7 million in upfront gross proceeds for the company.
- In a concurrent private placement, unregistered warrants to purchase up to 5,529,420 shares of common stock were issued at an exercise price of $1.50 per share, potentially yielding an additional $8.3 million in gross proceeds if fully exercised.
- The net proceeds from the offering are intended for working capital and general corporate purposes, including the continued development of novel medicines.
Sep 15, 2025, 8:35 PM
Cocrystal Pharma Showcases Norovirus Antiviral CDI-988 at International Conference
COCP
New Projects/Investments
- Cocrystal Pharma, Inc. showcased its lead pan-viral protease inhibitor, CDI-988, at the 9th International Calicivirus Conference held from September 7–11, 2025.
- President and co-CEO Sam Lee, PhD, presented the scientific foundation and clinical progress of CDI-988, highlighting its potential as the first oral antiviral in development for norovirus infection.
- Key findings from the Phase 1 study demonstrated CDI-988's favorable safety profile in human intestinal tissue and high exposure in the small intestine.
- The company recently completed its Phase 1 study and received FDA Investigation New Drug (IND) clearance for the next study.
- Cocrystal also announced FDA authorization to proceed with a Phase 1b human challenge study for CDI-988 as a potential norovirus prophylaxis and treatment, which is expected to begin before year end.
Sep 12, 2025, 9:30 PM
Cocrystal Pharma, Inc. announces registered direct offering and concurrent private placement
COCP
- Cocrystal Pharma, Inc. announced a registered direct offering of 2,764,710 shares of common stock (or equivalents) at $1.70 per share, expected to generate approximately $4.7 million in gross proceeds.
- Concurrently, the company will issue unregistered warrants to purchase up to 5,529,420 shares of common stock at an exercise price of $1.50 per share, with a potential to raise an additional $8.3 million if fully exercised.
- The offering is priced at-the-market under Nasdaq rules, and the closing is anticipated around September 15, 2025.
- The net proceeds from this offering are designated for working capital and general corporate purposes.
Sep 12, 2025, 9:30 PM
Cocrystal Pharma Highlights CDI-988 Clinical Progress for Norovirus Treatment
COCP
New Projects/Investments
- Cocrystal Pharma presented its lead pan-viral protease inhibitor, CDI-988, as a potential first oral antiviral for the prevention and treatment of norovirus infection at the 9th International Calicivirus Conference.
- The company recently completed a Phase 1 study for CDI-988, which demonstrated a favorable safety and tolerability profile with no serious adverse events.
- The U.S. FDA has granted Investigation New Drug (IND) clearance for the next study and authorized a Phase 1b human challenge study for CDI-988, which is expected to begin before year-end 2025.
Sep 12, 2025, 12:02 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more